This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, Y.-Z.
Right arrow Articles by Sun, Z.-W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, Y.-Z.
Right arrow Articles by Sun, Z.-W.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, December 2008, p. 1819-1823, Vol. 15, No. 12
1071-412X/08/$08.00+0     doi:10.1128/CVI.00239-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Evaluation of a Recombinant Hc of Clostridium botulinum Neurotoxin Serotype F as an Effective Subunit Vaccine{triangledown}

Yun-Zhou Yu, Na Li, Rui-Lin Wang, Heng-Qi Zhu, Shuang Wang, Wei-Yuan Yu, and Zhi-Wei Sun*

Beijing Institute of Biotechnology, 20 Dong Dajie Street, Fengtai District, Beijing 100071, China

Received 28 June 2008/ Returned for modification 6 August 2008/ Accepted 21 September 2008

A new gene encoding the Hc domain of Clostridium botulinum neurotoxin serotype F (FHc) was designed and completely synthesized with oligonucleotides. A soluble recombinant Hc of C. botulinum neurotoxin serotype F was highly expressed in Escherichia coli with this synthetic FHc gene. Subsequently, the purified FHc was used to vaccinate mice and evaluate their survival against challenge with active botulinum neurotoxin serotype F (BoNT/F). After the administration of FHc protein mixed with Freund adjuvant via the subcutaneous route, a strong protective immune response was elicited in the vaccinated mice. Mice that were given two or three vaccinations with a dosage of 1 or 10 µg of FHc were completely protected against an intraperitoneal administration of 20,000 50% lethal doses (LD50) of BoNT/F. The BoNT/F neutralization assay showed that the sera from these vaccinated mice contained high titers of protective antibodies. Furthermore, mice were vaccinated once, twice, or three times at four different dosages of FHc using Alhydrogel (Sigma) adjuvant via the intramuscular route and subsequently challenged with 20,000 LD50 of neurotoxin serotype F. A dose response was observed in both the antibody titer and the protective efficacy with increasing dosage of FHc and number of vaccinations. Mice that received one injection of 5 µg or two injections of ≥0.04 µg of FHc were completely protected. These findings suggest that the recombinant FHc expressed in E. coli is efficacious in protecting mice against challenge with BoNT/F and that the recombinant FHc subunit vaccine may be useful in humans.

* Corresponding author. Mailing address: Beijing Institute of Biotechnology, 20 Dongdajie St., Fengtai District, Beijing 100071, China. Phone: 86-10-63855329. Fax: 86-10-63833521. E-mail: yunzhouyu{at}163.com

{triangledown} Published ahead of print on 8 October 2008.

Clinical and Vaccine Immunology, December 2008, p. 1819-1823, Vol. 15, No. 12
1071-412X/08/$08.00+0     doi:10.1128/CVI.00239-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»